Skip to main content

Moberg Pharma signs exclusive agreement for Emtrix® in the Middle East and Africa

STOCKHOLM, November 5th, 2018, Moberg Pharma AB (OMX: MOB) has signed an exclusive agreement with Mundipharma to commercialize Emtrix® in the Middle East and Africa, starting in 2019.

Moberg Pharma signs an exclusive agreement with Mundipharma to commercialize Emtrix®, Moberg’s lead fungal nail product. Moberg Pharma will exclusively supply the product, and Mundipharma will be responsible for local registration and commercialization in the Middle East and Africa, focusing initially on three markets in the region.

“We look forward to developing our relationship with Mundipharma and making Emtrix® available in new regions as we expand our footprint in growing markets”, says Peter Wolpert, Moberg Pharma’s CEO.

“This newly signed agreement with Moberg Pharma will give onychomycosis patients in MEA region access to one of the leading treatments for this common and uncomfortable nail fungal condition”, said Dr. Ashraf Allam, Vice President of Mundipharma META.

About this information
This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 8.30 a.m. CET on November 5th, 2018.

About Emtrix® and Onychomycosis
Approximately 10% of the general population suffer from onychomycosis and a majority of those afflicted go untreated. The global market opportunity is significant with more than hundred million patients worldwide and a clear demand for better products. Emtrix® is a topical, prescription-free, over-the-counter product used to treat nail disease, also sold under the names Kerasal Nail® and Naloc™/Nalox™. Launched in late 2010, it quickly became the market leader in the Nordics and the best-selling product in its category in the U.S. Emtrix® has a unique and rapid mechanism of action, the safety and efficacy of which has been demonstrated in several clinical studies including more than 600 patients, most recently in a European clinical study in 2017 showing visible improvement after just one week for nails affected by onychomycosis and/or nail psoriasis.

For additional information, please contact:
Peter Wolpert, CEO, phone: Sweden: +46 707 35 7135, US: +1 908 432 2203, e-mail:

Eleonora Stern-Nejman, Investor relations, phone: +46 701 76 22 42, e-mail:

About Moberg Pharma,
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, New Skin®, Dermoplast® and Domeboro®. Kerasal Nail® (Emtrix®, Zanmira® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

About Mundipharma,
Mundipharma and its network of privately owned Independent Associated Companies (IACs) is dedicated to alleviating human suffering and improving quality of life for the human race. The Mundipharma story, spanning over six decades brings together a visionary approach and a pioneering spirit – what is best told through its patients, employees and the communities across six continents in which they serve. Mundipharma is focused on business transformation by leveraging global leadership in pain and, through a shared spirit of innovation, building a growing presence in antisepsis, respiratory, oncology, ophthalmology, consumer healthcare and other specialty areas.